The MHRA has advised healthcare professionals about the risk of acute pancreatitis associated with DPP-IV inhibitors (gl
- PDF / 136,139 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 100 Downloads / 170 Views
1
■ The MHRA has advised healthcare professionals about the risk of acute pancreatitis associated with DPP-IV inhibitors (gliptins). Pancreatitis is now included as a possible ADR in the product information for all DPP-IV inhibitors. Information on this ADR has come mostly from spontaneous postmarketing reports, and the reporting rate appears to be low (in the range of 0.1–1.0% of patients receiving the drug). Patients should be informed about the characteristics symptoms of acute pancreatitis (persistent, severe abdominal pain). MHRA. Dipeptidylpeptidase-4 inhibitors (‘gliptins’): risk of acute pancreatitis. Drug Safety Update 6: A3, No. 2, 1 Sep 2012. Available from: URL: http:// 803078067 www.mhra.gov.uk
0114-9954/10/1422-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 6 Oct 2012 No. 1422
Data Loading...
